Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

8506Background: Lurbinectedin (L) is a novel anticancer drug that inhibits activated transcription and induces DNA double-strand breaks, leading to apoptosis. Methods: A multicenter phase 2 basket ...